Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Abbvie Inc patents


Recent patent applications related to Abbvie Inc. Abbvie Inc is listed as an Agent/Assignee. Note: Abbvie Inc may have other listings under different names/spellings. We're not affiliated with Abbvie Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Abbvie Inc-related inventors


 new patent  Bispecific binding proteins

. . The present disclosure provides bispecific proteins that bind to two antigens, as well as their compositions, uses, and methods of making.. . ... Abbvie Inc

 new patent  Igm- or ige-modified binding proteins and uses thereof

Engineered binding proteins comprising a modified constant region, such as an igg constant region modified to contain a ch2 domain from an igm, a ch2 domain from an ige, or a variant thereof, are disclosed. The binding proteins can be multispecific, including bi-, tri-, and tetra-specific constructs. ... Abbvie Inc

 new patent  Anti-ox40 antibodies and their uses

The present disclosure provides novel anti-ox40 antibodies, compositions including the antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.. . ... Abbvie Inc

 new patent  Difluoroalkylcyclopropyl amino acids and esters, and syntheses thereof

The invention provides methods of synthesizing compounds in an asymmetric or enantioenriched fashion, wherein the compounds are useful intermediates in the synthesis of viral protease inhibitors.. . ... Abbvie Inc

Anti-cd40 antibodies and their uses

The present disclosure provides novel anti-cd40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.. . ... Abbvie Inc

Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

The present disclosure relates to processes for preparing (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.. . ... Abbvie Inc

Formulation obtained from a powder mixture comprising an inorganic pigment

A solid dosage form having a matrix with at least one active compound dispersed homogeneously in the matrix, which is obtainable by melting a powder mixture, wherein the powder mixture comprises at least one thermoplastic binder and a combination of highly disperse silica and at least one inorganic pigment, is described. The co-use of the highly disperse silica and the inorganic pigments leads to better flow properties of the powder mixture, has the effect of a faster release of the active compound from the dosage forms obtained, and imparts a visually pleasing appearance to the dosage forms. ... Abbvie Inc

Tricyclic modulators of tnf signaling

The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.. ... Abbvie Inc

Methods for treating hcv

The present invention features interferon-free therapies for the treatment of hcv. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. ... Abbvie Inc

Methods for treating hcv

The present invention features interferon-free therapies for treating hepatitis c virus (hcv) genotypes 1b, 2, 3 or 4. In one aspect, the therapies comprises administering compound 1 (paritaprevir), ritonavir, and compound 2 (ombitasvir) to a subject infected with hcv genotype 1b or 4, wherein the therapies do not include the administration of any interferon, and the therapies last from 8 to 12 weeks. ... Abbvie Inc

Anti-ox40 antibodies and their uses

The present disclosure provides novel anti-ox40 antibodies, compositions including the antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.. . ... Abbvie Inc

Novel modulators and methods of use

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.. . ... Abbvie Inc

Antibodies against the rgm a protein and uses thereof

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize rgm a protein. Specifically, these antibodies have the ability to inhibit the binding of rgm a to its receptor and/or coreceptors. ... Abbvie Inc

Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

The present disclosure relates to processes for preparing (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethy)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.. . ... Abbvie Inc

06/14/18 / #20180162586

Container assembly for shipping a product and method of forming the same

A container assembly is provided. The assembly includes a carrier portion including a plurality of side walls and a bottom wall, wherein the side walls and the bottom wall at least partially define a cavity of the carrier portion. ... Abbvie Inc

06/07/18 / #20180154079

Wearable automatic injection device for controlled delivery of therapeutic agents

Exemplary embodiments provide wearable automatic injection devices for subcutaneously injecting a therapeutic agent into a patient's body at controlled rates, for example, in a single bolus. Exemplary embodiments provide methods for assembling wearable automatic injection devices for subcutaneously injecting a therapeutic agent into a patient's body at controlled rates. ... Abbvie Inc

05/31/18 / #20180148513

Anti-pd-1 antibodies and their uses

The present disclosure provides novel anti-pd-1 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.. . ... Abbvie Inc

05/31/18 / #20180147358

Automatic injection devices having overmolded gripping surfaces

Exemplary embodiments provide automatic injection devices, housing components for automatic injection devices and methods for fabricating the same. An exemplary housing of an automatic injection device may be overmolded with one or more gripping surfaces to facilitate gripping and manipulation of the automatic injection device by a user when performing an injection. ... Abbvie Inc

05/24/18 / #20180141955

Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

The present disclosure relates to processes for preparing (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.. . ... Abbvie Inc

05/24/18 / #20180140595

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. . ... Abbvie Inc

05/17/18 / #20180133337

Calicheamicin constructs and methods of use

Provided herein are antibody drug conjugates (adcs) comprising calicheamicin and methods of using the same to treat proliferative disorders.. . ... Abbvie Inc

05/10/18 / #20180127506

Dac hyp compositions and methods

. . The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.. . ... Abbvie Inc

05/10/18 / #20180126000

Glucocorticoid receptor agonist and immunoconjugates thereof

Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.. . ... Abbvie Inc

05/10/18 / #20180125999

Anti-egfr antibodies and antibody drug conjugates

The invention relates to anti-epidermal growth factor (egfr) antibodies and antibody drug conjugates (adcs), including compositions and methods of using said antibodies and adcs.. . ... Abbvie Inc

04/19/18 / #20180105510

Salt and crystalline forms thereof of a drug

. . A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.. . ... Abbvie Inc

04/12/18 / #20180099094

Automatic injection device

. . Systems, methods, and devices are disclosed for facilitating injection of a medicament using an automatic injection device. The automatic injection device includes a housing defining a confined inner space and having a length extending from a proximal end to a distal end along a longitudinal axis. ... Abbvie Inc

04/05/18 / #20180094075

Anti-ptk7 antibody-drug conjugates

. . . . The present invention provides anti-ptk7 antibody-drug conjugates and methods for preparing and using the same.. . ... Abbvie Inc

04/05/18 / #20180094049

Amyloid-beta binding proteins

The present invention relates to amyloid-beta (aβ) binding proteins. Antibodies of the invention have high affinity to aβ(20-42) globulomer or any aβ form that comprises the globulomer epitope. ... Abbvie Inc

03/29/18 / #20180086737

Indazolones as modulators of tnf signaling

The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.. ... Abbvie Inc

03/29/18 / #20180085330

Dose adjustment

This application features dose adjustment for drugs co-administered with glecaprevir and pibrentasvir.. . ... Abbvie Inc

03/22/18 / #20180079808

Methods and compositions for treating asthma using anti-il-13 antibodies

The invention provides methods and compositions for treating asthma, e.g., mild or moderate asthma, in a subject using an anti-il-13 antibody, or antigen-binding portion thereof.. . ... Abbvie Inc

03/22/18 / #20180079762

Carbidopa and l-dopa prodrugs and methods of use

The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an l-dopa prodrug, and (c) methods of treating parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an l-dopa prodrug to a subject with parkinson's disease.. . ... Abbvie Inc

03/15/18 / #20180072810

Anti-pd-1 antibodies and their uses

. . The present disclosure provides novel anti-pd-1 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.. . ... Abbvie Inc

03/08/18 / #20180067120

Identification and enrichment of cell subpopulations

Markers useful for the identification, characterization and, optionally, the enrichment or isolation of tumorigenic cells or cell subpopulations are disclosed.. . ... Abbvie Inc

03/08/18 / #20180066044

Monoclonal antibodies against amyloid beta protein and uses thereof

The subject invention relates to monoclonal antibodies (e.g., 8f5 and 8c5) that may be used, for example, in the prevention, treatment and diagnosis of alzheimer's disease or other neurodegenerative disorders.. . ... Abbvie Inc

03/08/18 / #20180065961

Salts and crystalline forms of an apoptosis-inducing agent

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-({3-nitro-4-[(tetrahydro-2h-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic bcl-2 family proteins, for example cancer.. . ... Abbvie Inc

03/01/18 / #20180057502

Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

The present disclosure relates to processes for preparing (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyppyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.. . ... Abbvie Inc

03/01/18 / #20180057482

Synthetic route to anti-viral agents

The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.. . ... Abbvie Inc

02/15/18 / #20180044415

Anti-dll3 chimeric antigen receptors and methods of use

Provided herein are novel anti-dll3 chimeric antigen receptors and methods of using the same to treat proliferative disorders.. . ... Abbvie Inc

02/15/18 / #20180044414

Methods and compositions for treatment of skin disorders

The invention provides methods and compositions for the treatment of a skin disorder associated with detrimental tnfα activity, such as psoriasis. The invention includes methods for treating a skin disorder associated with detrimental tnfα activity, such as psoriasis, in a subject who has failed or lost response to prior biologic therapy, such as prior administration of etanercept. ... Abbvie Inc

02/15/18 / #20180042982

Methods for treating hcv

The present invention generally features interferon-free therapies for the treatment of hcv. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16, 12 or 8 weeks. ... Abbvie Inc

02/08/18 / #20180036422

Methods of delivering dll3 antibody drug conjugates

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. . ... Abbvie Inc

02/08/18 / #20180036421

Methods of making dll3 antibody drug conjugates

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. . ... Abbvie Inc

02/08/18 / #20180036407

Purified antibody composition

The invention provides a method for producing a host cell protein-(hcp) reduced antibody preparation from a mixture comprising an antibody and at least one hcp, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the hcp-reduced antibody preparation is obtained.. . ... Abbvie Inc

02/08/18 / #20180036393

Enzyme compositions with reduced viral and microbial contamination

The present invention pertains to an enzyme preparation obtained from e-beam irradiated animal tissue, such as porcine pancreas. The present invention also pertains to methods for making such enzyme preparations, pharmaceutical compositions comprising such enzymes preparations, and methods for using such pharmaceutical compositions and enzyme preparations.. ... Abbvie Inc

02/01/18 / #20180028454

Pharmaceutical compositions and methods of use thereof to treat pancreatic enzyme insufficiency

. . The present disclosure relates to pharmaceutical compositions comprising enzymes or enzyme mixtures having lipolytic and other optional other activities and methods of use thereof to treat exocrine pancreatic insufficiency.. . ... Abbvie Inc

01/25/18 / #20180022763

Anti-viral compounds

. . The present invention features compounds effective in inhibiting active against hepatitis c virus (“hcv”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat hcv infection.. ... Abbvie Inc

01/25/18 / #20180021280

Levodopa and carbidopa intestinal gel and methods of use

The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with parkinson's disease.. . ... Abbvie Inc

01/18/18 / #20180015178

Anti-dll3 antibody drug conjugates and methods of use

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. . ... Abbvie Inc

12/28/17 / #20170369571

Anti sez6 antibodies and methods of use

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. . ... Abbvie Inc

12/28/17 / #20170368195

Anti-dll3 antibody drug conjugates

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. . ... Abbvie Inc

12/28/17 / #20170368066

Solid antiviral dosage forms

The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.. . ... Abbvie Inc

12/21/17 / #20170362247

Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

The present disclosure relates to processes for preparing (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.. . ... Abbvie Inc

12/21/17 / #20170360783

Methods for treating hcv

The present invention features interferon-free therapies for the treatment of hcv. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. ... Abbvie Inc

12/14/17 / #20170355769

Anti-b7-h3 antibodies and antibody drug conjugates

The invention relates to b7 homology 3 protein (b7-h3) antibodies and antibody drug conjugates (adcs), including compositions and methods of using said antibodies and adcs.. . ... Abbvie Inc

12/14/17 / #20170355761

Cell culture methods to reduce acidic species

The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of acidic species expressed by host cells, as well as to compositions and processes for controlling the amount of acidic species present in purified preparations.. . ... Abbvie Inc

12/14/17 / #20170355760

Methods for modulating the glycosylation profile of recombinant proteins using sugars

The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of recombinant proteins expressed in host cells.. . ... Abbvie Inc

12/07/17 / #20170349655

Methods to modulate lysine variant distribution

The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the distribution or amount of lysine variants expressed by host cells, as well as to compositions and processes for controlling the amount of lysine variants present in purified preparations.. . ... Abbvie Inc

12/07/17 / #20170349654

Low acidic species compositions and methods for producing and using the same using displacement chromatography

The present invention relates to low acidic species (ar) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods for producing such low ar compositions using displacement chromatography. Methods for using such compositions to treat a disorder, e.g., a disorder in which tnfα is detrimental, are also provided.. ... Abbvie Inc

12/07/17 / #20170349653

Methods for treating spinal cord injury and pain

Disclosed herein are anti-rgma antibodies and methods of using these antibodies to treat spinal cord injury, including promoting axonal regeneration, functional recovery, or both and to treat pain, including neuropathic pain arising from spinal cord injury.. . ... Abbvie Inc

12/07/17 / #20170348429

Anti-cmet antibody drug conjugates and methods for their use

The present disclosure provides antibody drug conjugates that bind human cmet, their methods of making, and their uses to treat patients having cancer.. . ... Abbvie Inc

11/30/17 / #20170342169

Bispecific binding proteins

The present disclosure provides bispecific proteins that bind to two antigens, as well as their compositions, uses, and methods of making.. . ... Abbvie Inc

11/30/17 / #20170342159

Anti-cd40 antibodies and their uses

The present disclosure provides novel anti-cd40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.. . ... Abbvie Inc

11/30/17 / #20170342150

Method of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Compositions and methods for treating mm are provided herein.. . ... Abbvie Inc

11/30/17 / #20170342145

Protein purification using displacement chromatography

Disclosed herein are compositions and methods for the isolation and purification of proteins from a sample. In particular, the present invention relates to compositions and methods for isolating and purifying proteins incorporating a displacement chromatographic step. ... Abbvie Inc

11/30/17 / #20170342083

Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

The present disclosure relates to processes for preparing (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-c]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.. . ... Abbvie Inc

11/30/17 / #20170340737

Interleukin -13 binding proteins

The present invention encompasses il-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, cdr grafted and humanized antibodies. ... Abbvie Inc

11/23/17 / #20170334991

Anti-cldn chimeric antigen receptors and methods of use

Provided herein are novel anti-cldn chimeric antigen receptors and methods of using the same to treat proliferative disorders.. . ... Abbvie Inc

11/23/17 / #20170333428

Methods for treating hcv

The present invention features interferon-free therapies for the treatment of hcv. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. ... Abbvie Inc

11/09/17 / #20170320960

Novel anti-mfi2 antibodies and methods of use

. . Provided are novel anti-mfi2 antibodies and antibody drug conjugates, and methods of using such anti-mfi2 anti-bodies and antibody drug conjugates to treat cancer.. . ... Abbvie Inc

10/26/17 / #20170307622

Kits containing dll3 antibody drug conjugates

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. . ... Abbvie Inc

10/26/17 / #20170306010

Glycoengineered binding protein compositions

Provided are glycoengineered populations of fc domain-containing binding proteins with a reduced anti-drug immune response (ada). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions.. ... Abbvie Inc

10/26/17 / #20170306009

Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen

The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of recombinant proteins expressed in host cells by supplementing the production media with dissolved oxygen.. . ... Abbvie Inc

09/28/17 / #20170274094

Dll3 modulators and methods of use

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. . ... Abbvie Inc

09/28/17 / #20170274055

Enzyme compositions with reduced viral and microbial contamination

The present invention pertains to an enzyme preparation obtained from e-beam irradiated animal tissue, such as porcine pancreas. The present invention also pertains to methods for making such enzyme preparations, pharmaceutical compositions comprising such enzymes preparations, and methods for using such pharmaceutical compositions and enzyme preparations.. ... Abbvie Inc

09/21/17 / #20170266315

Anti-dll3 antibody drug conjugates for treating cancer

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. . ... Abbvie Inc

09/21/17 / #20170266314

Methods of making dll3 antibody drug conjugates

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. . ... Abbvie Inc

09/21/17 / #20170266313

Methods of delivering dll3 antibody drug conjugates

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. . ... Abbvie Inc

09/21/17 / #20170266312

Anti-dll3 antibody drug conjugates

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. . ... Abbvie Inc

09/21/17 / #20170266289

Topical formulation

The invention described herein provides topical formulations that can be prepared at ambient temperature without the need for any heating step during preparation. Thus the formulations are particularly suitable for cosmetic and pharmaceutical active ingredients that are relatively heat sensitive. ... Abbvie Inc

09/07/17 / #20170253562

Nampt inhibitors

. . Disclosed are compounds which inhibit the activity of nampt, compositions containing the compounds and methods of treating diseases during which nampt is expressed.. . ... Abbvie Inc

08/31/17 / #20170247461

Dac hyp compositions

The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.. . ... Abbvie Inc

08/31/17 / #20170247445

Mammalian cell culture performance through surfactant supplementation of feed media

The present invention provides methods for increasing cell culture performance through the use of chemically defined feed media (cdfm). In particular, the present invention provides methods for the use of surfactants as supplements to cdfm to allow for higher concentrations of media components and thereby result in increased cell culture performance.. ... Abbvie Inc

08/17/17 / #20170233481

Anti-cd25 antibodies and their uses

The present disclosure relates to antibodies directed to cd25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.. . ... Abbvie Inc

08/10/17 / #20170226552

Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt

The present invention relates to the field of protein production and, in particular, to methods and compositions for modulating the glycosylation of recombinant proteins expressed in host cells using cell culture media supplemented with cobalt.. . ... Abbvie Inc

08/10/17 / #20170226200

Dual variable domain immunoglobulins and uses thereof

Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.. . ... Abbvie Inc

08/03/17 / #20170218091

Monovalent binding proteins

Disclosed herein are engineered monovalent binding proteins that bind to one or more antigens, as well as methods of making and using the binding proteins in the prevention, diagnosis, and/or treatment of disease.. . ... Abbvie Inc

08/03/17 / #20170217850

Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose

The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.. . ... Abbvie Inc

07/27/17 / #20170210796

Stable dual variable domain immunoglobulin protein formulations

The invention provides stable aqueous formulations comprising an aqueous stable dual variable domain immunoglobulin (as-dvd-ig) protein. The invention also provides stable lyophilized formulations comprising a lyophilized stable dual variable domain immunoglobulin (ls-dvd-ig) protein.. ... Abbvie Inc

07/27/17 / #20170210795

Uses and compositions for treatment of psoriatic arthritis

The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a tnfα inhibitor, such as a human tnfα antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. ... Abbvie Inc

07/27/17 / #20170209344

Systems and methods for tubing delivery

Adapters for a connector assembly for percutaneous tubing are provided. A male adapter (fig. ... Abbvie Inc

07/20/17 / #20170203041

Automatic injection device

An automatic injection device for providing a injection is disclosed. The device includes a housing having a distal end operable by a user and an open proximal end for placement at an injection site. ... Abbvie Inc

07/13/17 / #20170198034

Methods to control protein heterogeneity

The instant invention relates to the field of protein production and in particular to controlled protein heterogeneity compositions and processes for controlling the heterogeneity of proteins expressed in host cells.. . ... Abbvie Inc

07/13/17 / #20170197980

N-(4-phenyl)-n'-(3-fluorophenyl)urea docusate

Docusate salts of n-(4-{4-amino-7-[1-(2-hydroxyethyl)-1h-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-n′-(3-fluorophenyl)urea are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.. . ... Abbvie Inc

07/06/17 / #20170190692

Atrasentan mandelate salts

The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method.. . ... Abbvie Inc

07/06/17 / #20170189620

Syringe with two-stage sealing pressure

A syringe includes a barrel, a plunger, and a sealing member creating a seal between the plunger and the barrel. The barrel includes a first portion with a first inner diameter and a second portion with a second inner diameter that is larger than the first inner diameter. ... Abbvie Inc

07/06/17 / #20170189426

Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor

The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising n-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1r)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl) propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or a salt, hydrate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer. The invention is further directed to processes for preparing the pharmaceutical dosage form and to use of the dosage form for treating proliferative disorders. ... Abbvie Inc

07/06/17 / #20170189402

Solid dosage forms

The present invention features solid dosage forms comprising two or more different active ingredients. In one embodiment, the present invention features a tablet dosage form comprising a first layer and a second layer, wherein the first layer comprises (1) 200 mg lopinavir, (2) ritonavir, (3) a pharmaceutically acceptable hydrophilic polymer, (4) a pharmaceutically acceptable surfactant, and (5) no more than 0.2% by weight of one or more lubricants, and the second layer comprises another therapeutic agent.. ... Abbvie Inc

07/06/17 / #20170189345

Nanoencapsulation of antigen-binding molecules

The present invention relates to nanospheres comprising a polymeric matrix and antigen-binding molecules esterase-releasably incorporated therein. The polymeric matrix is formed by poly(alkyl cyanoacrylates) and/or alkoxy derivatives thereof. ... Abbvie Inc

07/06/17 / #20170189344

Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules

The present invention relates to nanocapsules which are stabilized by a bile acid or salt thereof. The nanocapsules comprise a polymeric shell formed by poly(alkyl cyanoacrylates) and/or alkoxy derivatives thereof, wherein the polymeric shell encapsulates a core comprising an active agent. ... Abbvie Inc

06/29/17 / #20170182242

Wearable automatic injection device and related methods of use

Exemplary embodiments provide wearable automatic injection devices for providing an injection of a therapeutic agent into a patient. The wearable automatic injection device includes a housing having a patient contact portion securable to the patient, an injection needle for insertion into the patient, and a prefilled syringe assembly for holding the therapeutic agent. ... Abbvie Inc

06/29/17 / #20170182179

Antibody drug conjugates with cell permeable bcl-xl inhibitors

Small molecule bcl-xl inhibitors and antibody drug conjugates (adcs) comprising small molecule bcl-xl inhibitors are disclosed herein. The bcl-xl inhibitors and adcs of the disclosure are useful for, among other things, inhibiting anti-apoptotic bcl-xl proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.. ... Abbvie Inc

06/29/17 / #20170181973

Formulations of pyrimidinedione derivative compounds

The present disclosure relates to pharmaceutical compositions of pyrimidinedione derivative compounds and methods of preparing and uses thereof. The disclosure also relates to methods of enhancing bioavailability of pyrimidinedione derivative compounds in pharmaceutical compositions administered to a subject and methods of reducing the amount of a pyrimidinedione derivative compound in a pharmaceutical composition while achieving the same bioavailability in a subject.. ... Abbvie Inc

06/22/17 / #20170174672

Fused (hetero)cyclic compounds as s1p modulators

. . . . . . . . The invention relates to (hetero)cyclic compounds as s1p modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an s1p receptor.. . ... Abbvie Inc

06/22/17 / #20170173270

Self-injection tool with movable needle shroud

Self-injection tool includes a base and a shroud member. The base includes a proximal end, a distal end, and a barrel engagement portion. ... Abbvie Inc

06/22/17 / #20170172985

Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers

This invention pertains to a method for the treatment of non-small cell lung cancer in a subject who is a smoker, comprising administering to the subject an effective amount of 2-[(2r)-2-methylpyrrolidin-2-yl]-1h-benzimidazole-4-carboxamide (veliparib or abt-888), or a pharmaceutically acceptable salt thereof, in combination with carboplatin and paclitaxel.. . ... Abbvie Inc

06/15/17 / #20170166633

Antibodies against the rgm a protein and uses thereof

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize rgm a protein. Specifically, these antibodies have the ability to inhibit the binding of rgm a to its receptor and/or coreceptors. ... Abbvie Inc

06/08/17 / #20170158760

Isolation and purification of antibodies using protein a affinity chromatography

Disclosed herein are methods for the isolation and purification of antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise ph viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography, preferably protein a affinity, ion exchange chromatography, and hydrophobic chromatography. ... Abbvie Inc

06/08/17 / #20170158759

Formulation of human antibodies for treating tnf-alpha associated disorders

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a ph of between about 4 and about 8, and enhanced stability.. . ... Abbvie Inc

06/08/17 / #20170158758

Low acidic species compositions and methods for producing and using the same

The instant invention relates to low acidic species (ar) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low ar compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which tnfα is detrimental, are also provided.. ... Abbvie Inc

06/08/17 / #20170158693

Hexahydrodiazepinoquinolines carrying a cyclic radical

The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-ht2c receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-ht2c receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-ht2c receptor, and processes for preparing such compounds and compositions.. . ... Abbvie Inc

06/08/17 / #20170157249

Uses and compositions for treatment of rheumatoid arthritis

The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a tnfα inhibitor, such as a human tnfα antibody, or antigen-binding portion thereof. ... Abbvie Inc

06/08/17 / #20170157206

High purity oritavancin and method of producing same

Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.. . ... Abbvie Inc

06/08/17 / #20170157105

Anti-viral compounds

Compounds effective in inhibiting replication of hepatitis c virus (“hcv”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat hcv infection.. ... Abbvie Inc

06/08/17 / #20170157104

Anti-viral compounds

Compounds effective in inhibiting replication of hepatitis c virus (“hcv”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat hcv infection.. ... Abbvie Inc

06/08/17 / #20170156987

Systems and methods for tubing delivery

Connector assembly (fig. 4a) includes a shell (210), a connector body (230), and a plug (250). ... Abbvie Inc

06/01/17 / #20170152540

Compositions and methods for producing glycoproteins

The present disclosure relates to methods of producing antibodies with increased levels of non-fucosylated glycoforms by culturing mammalian cells in culture media with enhanced concentrations of glycine relative to traditional basal media.. . ... Abbvie Inc

06/01/17 / #20170151344

Anti-hulrrc15 antibody drug conjugates and methods for their use

The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human lrrc15, their methods of making, and their uses to treat patients having cancer.. . ... Abbvie Inc

06/01/17 / #20170151343

Anti-hulrrc15 antibody drug conjugates and methods for their use

The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human lrrc15, their methods of making, and their uses to treat patients having cancer.. . ... Abbvie Inc

06/01/17 / #20170151329

Formulation of human antibodies for treating tnf-alpha associated disorders

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a ph of between about 4 and about 8, and enhanced stability.. . ... Abbvie Inc

06/01/17 / #20170151238

Methods for treating hcv

The present invention features interferon-free therapies for the treatment of hcv. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. ... Abbvie Inc

05/18/17 / #20170137860

Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides

The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of proteins expressed in host cells.. . ... Abbvie Inc

05/18/17 / #20170137533

Anti-dll3 antibodies and drug conjugates for use in melanoma

Anti-dll3 antibodies and antibody drug conjugates for use in the diagnosis and treatment of melanoma.. . ... Abbvie Inc

05/18/17 / #20170137496

Methods to control protein heterogeneity

The instant invention relates to the field of protein production, and in particular to compositions and processes for controlling and limiting the heterogeneity of proteins expressed in host cells.. . ... Abbvie Inc

05/18/17 / #20170136122

Purified antibody composition

The invention provides a method for producing a host cell protein-(hcp) reduced antibody preparation from a mixture comprising an antibody and at least one hcp, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the hcp-reduced antibody preparation is obtained.. . ... Abbvie Inc

05/11/17 / #20170130191

Cell culture improvements

The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.. ... Abbvie Inc

05/11/17 / #20170129902

Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

The present disclosure relates to processes for preparing (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.. . ... Abbvie Inc

05/04/17 / #20170121416

Anti-cd324 monoclonal antibodies and uses thereof

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. . ... Abbvie Inc

05/04/17 / #20170121403

Modulated lysine variant species compositions and methods for producing and using the same

The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which tnfα is detrimental, are also provided.. ... Abbvie Inc

04/27/17 / #20170114129

Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration

The present application describes rgm a binding proteins, particularly monoclonal antibodies, and in particular cdr grafted, humanized versions thereof, which have the ability to bind to rgm a and prevent binding of rgm proteins to rgm a receptor and other rgm a binding proteins, and therefore neutralize the function of rgm a, for use in the treatment of retinal nerve fiber layer (rnfl) degeneration as well as methods of therapeutically or prophylactically treating a mammal against rnfl degeneration.. . ... Abbvie Inc

04/27/17 / #20170114077

Heterocyclic kinase inhibitors

The invention provides compounds of formula (i) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.. ... Abbvie Inc

04/27/17 / #20170112851

Hexahydrodiazepinoquinolines carrying a substituted alkyl radical

The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a substituted alkyl radical, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-ht2c receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-ht2c receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-ht2c receptor, and processes for preparing such compounds and compositions.. . ... Abbvie Inc

04/20/17 / #20170107038

Medication packaging and dispensing system

A medication packaging and dispensing system is provided. The system may include a plurality of medication booklets containing medication and a tray that is configured to retain the medication booklets. ... Abbvie Inc

04/13/17 / #20170101465

Use of tnfalpha antibody for treatment of hidradenitis suppurativa (hs)

The invention provides methods, uses and compositions for the treatment of hidradenitis suppurativa. The invention describes methods and uses for treating hidradenitis suppurativa, wherein a tnfα inhibitor, such as a human tnfα antibody, or antigen-binding portion thereof, is used to treat hidradenitis suppurativa in a subject. ... Abbvie Inc

04/06/17 / #20170096470

Dual specific binding proteins having a receptor sequence

Engineered multispecific binding proteins that bind at least one ligand for a receptor are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.. . ... Abbvie Inc

04/06/17 / #20170096424

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. . ... Abbvie Inc

03/30/17 / #20170088611

Single-chain multivalent binding protein compositions and methods

Provided are protein, nucleic acid, and cellular libraries of single chain multivalent binding proteins (e.g., scdvd and scdvdfab molecules) and methods of using these of these libraries for the screening of single chain multivalent binding proteins using cell surface display technology (e.g., yeast display).. . ... Abbvie Inc

03/23/17 / #20170081419

Novel modulators and methods of use

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.. . ... Abbvie Inc

03/23/17 / #20170079978

Therapy for complications of diabetes

A method for enhancing glycemic control and/or insulin sensitivity to a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin a (eta) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective eta receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective eta receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. ... Abbvie Inc

03/16/17 / #20170073430

Novel anti-rnf43 antibodies and methods of use

. . The invention discloses novel anti-rnf43 antibodies and derivatives thereof, including antibody drug conjugates, and methods of using such anti-rnf43 antibodies and antibody drug conjugates to diagnose and treat cancer.. . ... Abbvie Inc

03/16/17 / #20170073420

Methods for treating relapsing forms of multiple sclerosis

Disclosed herein are anti-rgma antibodies and methods of using these antibodies to treat multiple sclerosis, including relapsing forms of multiple sclerosis such as relapsing-remitting multiple sclerosis or relapsing-secondary progressive multiple sclerosis.. . ... Abbvie Inc

03/16/17 / #20170073329

Salt and crystalline forms thereof of a drug

A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.. . ... Abbvie Inc

03/16/17 / #20170072065

Anti-egfr antibodies and antibody drug conjugates

The invention relates to anti-epidermal growth factor (egfr) antibodies and antibody drug conjugates (adcs), including compositions and methods of using said antibodies and adcs.. . ... Abbvie Inc

03/09/17 / #20170066765

Crystalline bromodomain inhibitors

N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1h-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.. . ... Abbvie Inc

03/09/17 / #20170065575

Nampt inhibitors

Disclosed are compounds which inhibit the activity of nampt, compositions containing the compounds and methods of treating diseases during which nampt is expressed.. . ... Abbvie Inc

03/02/17 / #20170058027

Il-1 binding proteins

Proteins that bind il-1α and il-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing il-1-related disorders and for detecting il-1α and il-1β in cells, tissues, samples, and compositions.. . ... Abbvie Inc

03/02/17 / #20170057981

Anti-viral compounds

The present invention features compounds effective in inhibiting active against hepatitis c virus (“hcv”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat hcv infection.. ... Abbvie Inc

03/02/17 / #20170057966

Fused heterocyclic compounds as s1p modulators

The invention relates to heterocyclic compounds as s1p modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an s1p receptor.. . ... Abbvie Inc

03/02/17 / #20170056498

Formulation of human antibodies for treating tnf-alpha associated disorders

A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a ph of between about 4 and about 8, and enhanced stability.. . ... Abbvie Inc

03/02/17 / #20170056403

Methods of administering elagolix

The present disclosure relates to the use of gnrh receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.. ... Abbvie Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Abbvie Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Abbvie Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###